› $4.85 Billion settlement in drug case
Responding to widespread pressure from many congressmen, veteran’s organizations, and the general public, the Veterans Administration announced today that it would directly notify all of its veterans currently using Pfizer’s new smoking cessation drug Chantix. The number of veterans on Chantix is approximately 32,000.
On Monday ABC News and The Washington Times broke a report on the Veterans Administration testing Pfizer’s smoking cessation drug Chantix on 140 veterans suffering from Post Traumatic Stress Disorder (PTSD). The VA administered the drug to the soldiers without warning them about months-old discoveries linking Chantix to a range of neuropsychiatric behavior and illness, including depression, loss of sleep, vivid dreams, suicidal thoughts, and suicidal actions.
According to an article published by Bloomberg news service, a recent review of voluntary adverse event reports associated with Pfizer’s stop-smoking drug Chantix reveals more than 3,000 reports of serious side effects in the U.S. alone. Among problems cited by the nonprofit Institute for Safe Medication Practices, which conducted the study, are suicide, heart trouble and aggression.
Once hailed as a miracle drug for helping people to stop smoking, Pfizer’s Chantix has recently raised concerns as reports surface that it may have a disturbing side effect – suicidal thoughts and actions. A report in the New Jersey Star-Ledger notes that the FDA is investigating reports of a number of serious psychological side effects. In additon to suicidal actions, reports include agitation and depression.
